Skip to main content
SpringerLink
Log in

Makrovaskuläre Sekundärprävention mit Pioglitazon bei Diabetikern

PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events)

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Bertoni AG, Hundley WG, Massing MW et al. (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27: 699–703

    PubMed  Google Scholar 

  2. Haffner SM, Lehto S, Ronnemaa T et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234

    PubMed  Google Scholar 

  3. Seufert J (2006) Cardiovascular outcome studies in type 2 diabetes therapy. Dtsch Arztebl 103: A 934–942

    Google Scholar 

  4. Yudkin JS, Freemantle N (2006) PROactive study. Lancet 367: 24--25; author reply 26–27

    Article  PubMed  Google Scholar 

  5. Yki-Jarvinen H (2005) The PROactive study: some answers, many questions. Lancet 366: 1241–1242

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der Autor hat Referentenhonorare von Takeda Pharmaceutical Company erhalten. Trotz des möglichen Interessenkonfliktes ist der Beitrag unabhängig und produktneutral.

Author information

Authors and Affiliations

  1. ?OrgName?, 70619, Fridinger Str. 16a, Stuttgart, Deutschland

    S. Nitschmann

Authors
  1. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Nitschmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nitschmann, S. Makrovaskuläre Sekundärprävention mit Pioglitazon bei Diabetikern. Internist 48, 89–92 (2007). https://doi.org/10.1007/s00108-006-1777-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-006-1777-6

Search

Navigation